Literature DB >> 8370410

Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions.

T Bellón1, A Corbí, P Lastres, C Calés, M Cebrián, S Vera, S Cheifetz, J Massague, M Letarte, C Bernabéu.   

Abstract

Endoglin is an homodimeric membrane antigen with capacity to bind transforming growth factor-beta (TGF-beta) and whose expression is up-regulated on myeloid cells upon differentiation to macrophages. We have isolated full-length cDNA clones from a lambda gt 10 library, prepared from phorbol 12-myristate 13-acetate-differentiated HL60 cells by screening with an endoglin-specific cDNA probe from endothelial cells. Sequencing of the largest clone (3073 bp), revealed that the leader sequence contains 25 residues and that the 586 amino acids of the extracellular and transmembrane domains were identical to those described for endothelial endoglin. However, the cytoplasmic tail encoded by this cDNA clone contains only 14 amino acids as opposed to the 47 residues previously reported, suggesting the existence of two alternative endoglin variants. The expression of these isoforms was demonstrated by polymerase chain reaction analyses on endothelial cells, myelomonocytic cell lines HL-60 and U-937, and placenta. Independent cDNA constructs corresponding to both forms were transfected into mouse fibroblasts leading to the expression of two distinct endoglin molecules. Both forms were shown to bind TGF-beta 1 and, when overexpressed in transfected mouse fibroblasts, to form disulfide-linked homodimers, indicating that the cysteine residues present in the extracellular domain are responsible for the dimerization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370410     DOI: 10.1002/eji.1830230943

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  51 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Endoglin suppresses human prostate cancer metastasis.

Authors:  Minalini Lakshman; Xiaoke Huang; Vijayalakshmi Ananthanarayanan; Borko Jovanovic; Yueqin Liu; Clarissa S Craft; Diana Romero; Calvin P H Vary; Raymond C Bergan
Journal:  Clin Exp Metastasis       Date:  2010-10-28       Impact factor: 5.150

Review 3.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

4.  Endoglin and Alk5 regulate epithelial-mesenchymal transformation during cardiac valve formation.

Authors:  Melania E Mercado-Pimentel; Antony D Hubbard; Raymond B Runyan
Journal:  Dev Biol       Date:  2006-12-23       Impact factor: 3.582

Review 5.  BMP signaling in vascular development and disease.

Authors:  Jonathan W Lowery; Mark P de Caestecker
Journal:  Cytokine Growth Factor Rev       Date:  2010-07-31       Impact factor: 7.638

6.  Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth.

Authors:  Roselyne Castonguay; Eric D Werner; Robert G Matthews; Eleonora Presman; Aaron W Mulivor; Nicolas Solban; Dianne Sako; R Scott Pearsall; Kathryn W Underwood; Jasbir Seehra; Ravindra Kumar; Asya V Grinberg
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

7.  Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia.

Authors:  F S Govani; A Giess; I G Mollet; M E Begbie; M D Jones; L Game; C L Shovlin
Journal:  Mol Syndromol       Date:  2013-04-11

8.  Expression of normal and truncated forms of human endoglin.

Authors:  U Raab; B Velasco; P Lastres; A Letamendía; C Calés; C Langa; E Tapia; J P López-Bote; E Páez; C Bernabéu
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

9.  Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis.

Authors:  Maria L Mancini; Aleksandra Terzic; Barbara A Conley; Leif H Oxburgh; Teodora Nicola; Calvin P H Vary
Journal:  Dev Dyn       Date:  2009-10       Impact factor: 3.780

10.  Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative.

Authors:  N Pece; S Vera; U Cymerman; R I White; J L Wrana; M Letarte
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.